SILO

SILO Pharma Inc

6.17

Jul 01 • 04:00PM ET -0.04 (-0.64%)

Healthcare Biotechnology USA Nano NASD

Peers: APRE BCDA BIVI CALC CVM GOVX KAPA KPRX LNAI NEUP

| Held by: PSIL VXF

Scroll to Statements

Index	-
Market Cap	6.96M
Enterprise Value	0.69M
Income	-4.84M
Sales	0.07M
Book/sh	5.24
Cash/sh	5.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	3
IPO	May 13, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	99.43
P/B	1.18
P/C	1.11
P/FCF	-
EV/EBITDA	-
EV/Sales	9.86
Quick Ratio	9.65
Current Ratio	9.65
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-7.46
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	33.45% 26.52%
Sales past 3/5Y	0.00% -
EPS Y/Y TTM	56.28%
Sales Y/Y TTM	0.00%
EPS Q/Q	47.76%
Sales Q/Q	0.00%
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	1.69%
Insider Trans	0.00%
Inst Own	6.24%
Inst Trans	-
ROA	-74.99%
ROE	-99.94%
ROIC	-85.24%
Gross Margin	-1244.34%
Oper. Margin	-6631.16%
Profit Margin	-6717.40%
SMA20	-0.23%
SMA50	-2.20%
SMA200	-6.86%
Trades

Shs Outstand	1.13M
Shs Float	1.11M
Short Float	1.51%
Short Ratio	0.06
Short Interest	0.02M
52W High	15.15 -59.27%
52W Low	3.32 86.12%
Volatility	7.77% 9.38%
ATR (14)	0.55
RSI (14)	50.47
Beta	0.78
Rel Volume	0.23
Avg Volume	294.53K
Volume	65,864

Perf Week	-0.80%
Perf Month	23.67%
Perf Quarter	14.35%
Perf Half Y	23.01%
Perf YTD	20.98%
Perf Year	-33.01%
Perf 3Y	-79.93%
Perf 5Y	-96.42%
Perf 10Y	-99.18%
Recom	1.00
Target Price	150.00
Prev Close	6.21
Price	6.17
Change	-0.64%

Jun-29-26 04:15PM	Silo Pharma Advances SPC-15 PTSD Therapeutic with Drug-Device Robustness Study Ahead of Planned FDA Type C Meeting Request (GlobeNewswire)
Jun-23-26 08:17AM	Silo Pharma Reports Positive Stability Data for SPC-15 PTSD Treatment, Advancing Program Toward First-in-Human Clinical Trial (GlobeNewswire)
Jun-18-26 08:12AM	Silo Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +5.34%
May-07-26 08:05AM	Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury (GlobeNewswire)
May-04-26 11:11AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
09:08AM	Loading…
Apr-29-26 09:08AM	Silo Pharma's PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD (GlobeNewswire)
Apr-22-26 04:15PM	Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents (GlobeNewswire) -8.13% -16.85%
Apr-20-26 06:34AM	Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics (GlobeNewswire) +29.34%
Apr-13-26 10:39AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Apr-06-26 04:15PM	Silo Pharma Receives European Patent Allowance for Licensed Novel PTSD Prevention Therapy (GlobeNewswire) +49.02%
Feb-23-26 04:15PM	Silo Pharma Announces Share Buyback Program (GlobeNewswire) +24.00%
Feb-18-26 08:28AM	Silo Pharma Receives Notice of Allowance in Japan for SPC-15, Expanding Global Intellectual Property Portfolio (GlobeNewswire)
Dec-30-25 08:05AM	Silo Pharma Executes Letter of Intent with Allucent to Support Phase 1 Clinical Development of SPC-15 (GlobeNewswire)
Nov-17-25 08:05AM	Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD (GlobeNewswire)
Oct-29-25 08:25AM	Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain (GlobeNewswire)
08:45AM	Loading…
Oct-23-25 08:45AM	Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program (GlobeNewswire)
Oct-13-25 09:30AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +11.78%
Oct-08-25 08:45AM	Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth (GlobeNewswire)
Oct-06-25 08:10AM	Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci) (GlobeNewswire)
Oct-01-25 04:20PM	Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Sep-30-25 08:02AM	Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -7.95%
Sep-29-25 02:30PM	Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management (GlobeNewswire)
Sep-23-25 08:38AM	Silo Pharma Signs Strategic Agreement with Fireblocks to Advance Crypto Treasury Strategy Acquisition and Security (GlobeNewswire)
08:16AM	EXCLUSIVE: Silo Pharma Partners With Fireblocks To Advance Crypto Treasury Strategy Acquisition And Security (Benzinga)
Sep-16-25 08:11AM	Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy (GlobeNewswire) -9.27%
Sep-09-25 06:45PM	3 Under-the-Radar Biotechs Under $5 That Could Soar 200% (MarketBeat) +9.19%
09:10AM	Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug (GlobeNewswire)
Sep-07-25 05:29PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-03-25 08:25AM	Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio (GlobeNewswire)
Sep-02-25 07:46AM	EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers (Benzinga)
02:00PM	Loading…
Aug-21-25 02:00PM	Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal (GlobeNewswire)
Aug-19-25 08:05AM	Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway (GlobeNewswire) -6.54%
Aug-05-25 08:32AM	Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform (GlobeNewswire) -17.57%
Jul-16-25 08:45AM	Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 (GlobeNewswire)
Jul-07-25 08:15AM	Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 (GlobeNewswire)
Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-25-25 08:38AM	Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market (GlobeNewswire)
08:27AM	Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. (PR Newswire)
Jun-16-25 05:44PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jun-11-25 09:00AM	Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears (GlobeNewswire)
Jun-05-25 09:15AM	Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset (GlobeNewswire) +12.08%
May-21-25 08:55AM	Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15 (GlobeNewswire) -8.84%
May-16-25 04:15PM	Silo Pharma Announces Closing of $2 Million Public Offering (GlobeNewswire) -7.04%
May-15-25 09:15AM	Silo Pharma Announces Pricing of $2 Million Public Offering (GlobeNewswire) -37.81%
May-14-25 04:07PM	Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15 (GlobeNewswire) -24.00%
08:40AM	Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories (GlobeNewswire)
Apr-30-25 08:11AM	Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study (GlobeNewswire) -7.41%
Apr-28-25 07:50AM	Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug (GlobeNewswire) -26.95%
Mar-26-25 08:40AM	Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment (GlobeNewswire)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-26-25 01:30PM	Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment (GlobeNewswire)
Feb-18-25 08:50AM	Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment (GlobeNewswire)
Feb-11-25 07:45AM	Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia (GlobeNewswire)
Jan-22-25 08:29AM	Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment (GlobeNewswire)
Jan-09-25 08:36AM	Silo Pharma awarded U.S. patent for PTSD treatment (TipRanks)
Jan-08-25 08:29AM	Silo Pharma Awarded US Patent for Groundbreaking PTSD Treatment and Prepares for SPC-15 Clinical Trial (GlobeNewswire) +56.88%
Jan-02-25 08:45AM	Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain (GlobeNewswire) +6.74%
Dec-19-24 07:40AM	Silo Pharma initiates pharmacokinetic, tolerability study for SP-26 (TipRanks)
Dec-18-24 07:35AM	Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia (GlobeNewswire) -15.33%
Nov-29-24 08:05AM	Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management (GlobeNewswire) +11.11%
Nov-18-24 08:40AM	Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders (GlobeNewswire) -12.39%
Oct-31-24 08:35AM	Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant (GlobeNewswire)
Sep-10-24 06:35AM	Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD (GlobeNewswire) -13.01%
Aug-14-24 02:30PM	Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic (GlobeNewswire) +9.60%
Aug-07-24 08:13AM	Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide (GlobeNewswire) -13.24%
Jul-26-24 08:20AM	Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference (GlobeNewswire) +9.95%
Jul-22-24 04:45PM	Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jul-19-24 08:01AM	Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -29.11%
Jul-18-24 08:25AM	Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15 (GlobeNewswire) +54.22%
Jul-16-24 08:00AM	Why Is Silo Pharma (SILO) Stock Up 123% Today? (InvestorPlace) +123.36%
07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
06:30AM	Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic (GlobeNewswire)
Jul-08-24 08:45AM	Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders (GlobeNewswire) -5.19%
Jun-26-24 08:50AM	Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety (GlobeNewswire) -6.48%
Jun-07-24 08:18AM	Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia (GlobeNewswire)
Jun-06-24 04:50PM	Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Jun-05-24 08:00AM	Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -46.67%
Jun-04-24 08:41AM	Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety (GlobeNewswire) +10.84%
May-21-24 08:45AM	Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention (GlobeNewswire) +7.39%
May-14-24 08:45AM	Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine (GlobeNewswire)
Apr-23-24 08:15AM	Silo Pharma Announces Positive Results for Intranasal PTSD Treatment (GlobeNewswire) -10.55%
Apr-14-24 03:00PM	10 Micro-Cap Healthcare Stocks Insiders Are Buying (Insider Monkey)
Apr-10-24 08:11AM	Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic (GlobeNewswire)
Apr-02-24 03:12PM	Hedge Fund and Insider Trading News: Ray Dalio, Steven Tananbaum, Steve Cohen, Crispin Odey, Ken Griffin, Third Point LLC, Westlake Chemical Partners LP (WLKP), and More (Insider Monkey)
Mar-20-24 08:30AM	Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic (GlobeNewswire)
Mar-18-24 07:15AM	Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain (GlobeNewswire)
Feb-28-24 08:25AM	Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD (GlobeNewswire)
Feb-14-24 08:45AM	Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery (GlobeNewswire) +5.63%
Feb-01-24 10:00AM	Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology (GlobeNewswire)
Jan-24-24 08:55AM	Silo Pharma Announces Positive Results in Alzheimer's Disease Study (GlobeNewswire) +5.71%
Jan-04-24 08:55AM	Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD (GlobeNewswire)
Dec-28-23 08:25AM	Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia (GlobeNewswire) -11.00%
Nov-21-23 08:01AM	Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD (GlobeNewswire) +12.93%
Nov-08-23 08:11AM	Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD (GlobeNewswire)
Oct-16-23 08:11AM	Silo Pharma's SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis (GlobeNewswire) -7.28%
Oct-11-23 08:35AM	Silo Pharma Initiates Human Factor Study of SPC-15 for the Treatment of PTSD (GlobeNewswire)
Sep-20-23 08:28AM	Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA (GlobeNewswire)
Sep-12-23 08:50AM	Silo Pharma Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD (GlobeNewswire)
Aug-10-23 08:50AM	Silo Pharma Engages Clarivate for Intellectual Property and Patent Management (GlobeNewswire)
Aug-08-23 08:30AM	Silo Pharma Reaches Positive Milestone with Nasal Formulation of SPC-15 For Anxiety, PTSD, and Stress-Related Disorders (GlobeNewswire)

Silo Pharma, Inc. is a developmental stage biopharmaceutical company, which engages in the merging of traditional therapeutics with psychedelic research. It seeks to acquire and develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs. The company was founded by Eric Weisblum on July 13, 2010 and is headquartered in Sarasota, FL.

ChairmanMr. Eric Weisblum

Chief Financial OfficerMr. Daniel E. Ryweck

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Weisblum Eric	Chief Executive Officer	Dec 15 '25	Buy	0.41	5,000	2,075	216,932	Dec 16 06:34 PM
Weisblum Eric	Chief Executive Officer	Nov 20 '25	Buy	0.37	1,000	370	210,932	Nov 21 06:35 PM
Weisblum Eric	Chief Executive Officer	Nov 21 '25	Buy	0.36	1,000	365	211,932	Nov 21 06:35 PM
Weisblum Eric	Chief Executive Officer	Nov 18 '25	Buy	0.40	7,500	3,025	205,432	Nov 20 04:00 PM
Weisblum Eric	Chief Executive Officer	Nov 19 '25	Buy	0.41	4,500	1,823	209,932	Nov 20 04:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

SILO

SILO Pharma Inc

Upgrade your Finviz experience